pulmicort dreifa í eimgjafa 0,125 mg/ml
astrazeneca a/s - budesonidum inn - dreifa í eimgjafa - 0,125 mg/ml
pulmicort dreifa í eimgjafa 0,25 mg/ml
astrazeneca a/s - budesonidum inn - dreifa í eimgjafa - 0,25 mg/ml
pulmicort dreifa í eimgjafa 0,5 mg/ml
astrazeneca a/s - budesonidum inn - dreifa í eimgjafa - 0,5 mg/ml
pulmicort turbuhaler innöndunarduft 100 míkróg/skammt
astrazeneca a/s - budesonidum inn - innöndunarduft - 100 míkróg/skammt
pulmicort turbuhaler innöndunarduft 200 míkróg/skammt
astrazeneca a/s - budesonidum inn - innöndunarduft - 200 míkróg/skammt
pulmicort turbuhaler innöndunarduft 400 míkróg/skammt
astrazeneca a/s - budesonidum inn - innöndunarduft - 400 míkróg/skammt
tepkinly
abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - Æxlishemjandi lyf - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.
kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - Önnur æxlishemjandi lyf - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
soluprick sq (grass pollen) húðstungupróf, lausn 10 hep
alk-abelló a/s - phleum pratense; avena elatior; alopecurus pratensis; secale cereale; poa pratensis; dactylis glomerata; festuca pratensis; lolium perenne - húðstungupróf, lausn - 10 hep
soluprick negativ kontrol húðstungupróf, lausn
alk-abelló a/s - húðstungupróf, lausn